Mr. Barnes joined QuiqMeds in May 2017 as Executive Chairman of the Board of Directors and assumed the role of CEO in September 2017.
Through a unique combination of c—suite leadership experience Mr. Barnes has demonstrated success in launching innovative products and services companies impacting both the healthcare and pharmaceutical business industries. He has successfully aligned business strategies and operational tactics through decisive leadership to guide enterprises through start-up, rapid growth, turnaround and revitalization phases.
Prior to joining QuiqMeds Mr. Barnes was the founder and CEO of VirMedica, Inc., an e-access and technology company. He also founded and served as CEO of Livingston Healthcare in the U.S. now a UPS company.
Mr. Barnes attended Iowa State and Rutgers University.
Thomas Bergmann, is COO of NobleHouse Consulting Ltd., a Hong Kong based multifamily office in Switzerland, where he responsibly manages investments and operations of international European families, including asset management and family affairs as well as support in M&A, private and public offerings. In this capacity, he served as CEO of the US based pharmaceutical company Macromed Inc., which was sold to a large publicly traded pharmaceutical company in the UK. Previously he also worked at Daimler AG in various sales, IT, and senior management positions including business development in Switzerland and Germany. Bergmann represents the interests of the managed families in various Boards of Directors. He served as Chairman of the Board of the US based company QuiqMeds Inc. where he is still Member of the Board. Further he served as Chairman of the Board of BioEqual, a Swiss based development company for cosmetics and medical devices. In addition, he serves as Director of the Board of the Swiss based subsidiaries of Antares Pharma Inc. (Nasdaq: ATRS). Further to this he serves as Member of the Board on various private companies in Switzerland. Bergmann studied IT and Economics at the VWA in Stuttgart, Germany and holds an MBA degree.
Leonard S. Jacob M.D., Ph.D., D.Sc. (Hon) Dr. Jacob received his M.D. from the Medical College of Pa. in 1978 and served on its Board from 1986 to 1998. He currently serves as Chairman of the Board of Antares Pharma. Inc., a publicly traded drug delivery and device company. He also serves on Board of the University of the Sciences and the Temple University School of Medicine. Previously, Dr. Jacob served as worldwide vice president of SmithKline Pharmaceutical Co. and was a member of their Corporate Management Committee. For the past two decades he has been an entrepreneur, co-founding, the Genaera Corp., a publicly traded biotechnology company and InKine Pharmaceuticals a publicly traded gastrointestinal specialty pharmaceutical company. Recently, Dr. Jacob served as Chairman of Bradley Pharmaceuticals.
Dr. Jacob has overseen the development of seven prescribed drugs impacting human health and is the named inventor on six patents. In 2004, Dr. Jacob was given the outstanding alumnus award from the Temple University School of Medicine. In 2008 he was bestowed an honorary doctor of science degree by the University of the Sciences and in early 2010 he was given the “outstanding entrepreneur award” and later that year “the distinguished achievement award in clinical research” from the Drexel University School of Medicine.
Lawrence Jay Kessel, M.D. F.A.C.P. has served on our Board of Directors since November 2006. Since 1984, Dr. Kessel has served as President of Lawrence J. Kessel, M.D. & Associates, PC, a physician practice specializing in internal medicine and geriatrics. He completed a formal residency in Internal Medicine at Abington Memorial Hospital and is Board Certified in Internal Medicine and Geriatric Medicine. He is an active attending staff and clinical instructor at Chestnut Hill Hospital (University of Pennsylvania affiliate) and Roxborough Memorial Hospital in Philadelphia, Pennsylvania. Dr. Kessel previously served on the boards of Cypress Biosciences, Inc., NovaDel Pharma Inc., and Dor BioPharma, Inc. and KERYX inc. He received his B.S. from the University of Pittsburgh and his M.D. from the Temple University School of Medicine. Dr. Kessel is a board reviewer for the American Board of Internal Medicine, and a Fellow of the American College of Physicians. Dr. Kessel served on the advisory board of Independence Blue Cross and is a clinical assistant professor in the department of medicine at Temple University Medical School.